ShareProphets

The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join ShareProphets at less than 2p per article

> Hot share tips

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Accrol – after 2016 IPO at 100p & 2017 bailout placing at 50p, what now?

By Steve Moore | Wednesday 16 May 2018


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


In June 2016 tissue products manufacturer Accrol (ACRL) listed on AIM, raising £63.5 million at 100p per share. Just seventeen months later it was bailout fundraising at half of the IPO price but still recently “revised banking arrangements” have been necessary and now at 3:08pm on 15th May 2018…


Filed under:



This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.




Site by Everywhen